Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test
Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.
Real-time market intelligence across asset classes
Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.
Abbott Laboratories agreed to acquire cancer-screening company Exact Sciences Corp., in a deal with a total equity value of about …
US equity futures advance as an upbeat forecast from Nvidia soothes fears of an AI spending bubble. Investors brace for …
US president endorses move to restrict regulation by states after lobbying from Silicon Valley
Investors are worried that tech companies are overspending on artificial intelligence and there's a bubble that could burst.
Home buyers, start your engines and get ready to race to the real estate finish line—where the chance to snap …
Multi-Provider AI Analysis